Skating to where the puck is going to be

A plan for clinical trials and translation research in mood disorders

Ellen Frank, A. John Rush, Mary Blehar, Susan Essock, William Hargreaves, Michael Hogan, Robin Jarrett, Robert Johnson, Wayne J. Katon, Phillip Lavori, James P. McNulty, George Niederehe, Neal Ryan, Gail Stuart, Stephen B. Thomas, Gary D. Tollefson, Benedetto Vitiello

    Research output: Contribution to journalReview article

    18 Citations (Scopus)

    Abstract

    As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.

    Original languageEnglish (US)
    Pages (from-to)631-654
    Number of pages24
    JournalBiological Psychiatry
    Volume52
    Issue number6
    DOIs
    StatePublished - Sep 15 2002

    Fingerprint

    Skating
    Mood Disorders
    Clinical Trials
    Research
    Therapeutics
    Learning
    National Institute of Mental Health (U.S.)
    Costs and Cost Analysis
    Recurrence
    Geriatrics
    Population
    Cost-Benefit Analysis

    All Science Journal Classification (ASJC) codes

    • Biological Psychiatry

    Keywords

    • Clinical trials
    • Mood disorders
    • Translation research

    Cite this

    Frank, E., Rush, A. J., Blehar, M., Essock, S., Hargreaves, W., Hogan, M., ... Vitiello, B. (2002). Skating to where the puck is going to be: A plan for clinical trials and translation research in mood disorders. Biological Psychiatry, 52(6), 631-654. https://doi.org/10.1016/S0006-3223(02)01467-1
    Frank, Ellen ; Rush, A. John ; Blehar, Mary ; Essock, Susan ; Hargreaves, William ; Hogan, Michael ; Jarrett, Robin ; Johnson, Robert ; Katon, Wayne J. ; Lavori, Phillip ; McNulty, James P. ; Niederehe, George ; Ryan, Neal ; Stuart, Gail ; Thomas, Stephen B. ; Tollefson, Gary D. ; Vitiello, Benedetto. / Skating to where the puck is going to be : A plan for clinical trials and translation research in mood disorders. In: Biological Psychiatry. 2002 ; Vol. 52, No. 6. pp. 631-654.
    @article{cfb6c9f505de410cb33b3dcb402f2840,
    title = "Skating to where the puck is going to be: A plan for clinical trials and translation research in mood disorders",
    abstract = "As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.",
    keywords = "Clinical trials, Mood disorders, Translation research",
    author = "Ellen Frank and Rush, {A. John} and Mary Blehar and Susan Essock and William Hargreaves and Michael Hogan and Robin Jarrett and Robert Johnson and Katon, {Wayne J.} and Phillip Lavori and McNulty, {James P.} and George Niederehe and Neal Ryan and Gail Stuart and Thomas, {Stephen B.} and Tollefson, {Gary D.} and Benedetto Vitiello",
    year = "2002",
    month = "9",
    day = "15",
    doi = "10.1016/S0006-3223(02)01467-1",
    language = "English (US)",
    volume = "52",
    pages = "631--654",
    journal = "Biological Psychiatry",
    issn = "0006-3223",
    publisher = "Elsevier USA",
    number = "6",

    }

    Frank, E, Rush, AJ, Blehar, M, Essock, S, Hargreaves, W, Hogan, M, Jarrett, R, Johnson, R, Katon, WJ, Lavori, P, McNulty, JP, Niederehe, G, Ryan, N, Stuart, G, Thomas, SB, Tollefson, GD & Vitiello, B 2002, 'Skating to where the puck is going to be: A plan for clinical trials and translation research in mood disorders', Biological Psychiatry, vol. 52, no. 6, pp. 631-654. https://doi.org/10.1016/S0006-3223(02)01467-1

    Skating to where the puck is going to be : A plan for clinical trials and translation research in mood disorders. / Frank, Ellen; Rush, A. John; Blehar, Mary; Essock, Susan; Hargreaves, William; Hogan, Michael; Jarrett, Robin; Johnson, Robert; Katon, Wayne J.; Lavori, Phillip; McNulty, James P.; Niederehe, George; Ryan, Neal; Stuart, Gail; Thomas, Stephen B.; Tollefson, Gary D.; Vitiello, Benedetto.

    In: Biological Psychiatry, Vol. 52, No. 6, 15.09.2002, p. 631-654.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Skating to where the puck is going to be

    T2 - A plan for clinical trials and translation research in mood disorders

    AU - Frank, Ellen

    AU - Rush, A. John

    AU - Blehar, Mary

    AU - Essock, Susan

    AU - Hargreaves, William

    AU - Hogan, Michael

    AU - Jarrett, Robin

    AU - Johnson, Robert

    AU - Katon, Wayne J.

    AU - Lavori, Phillip

    AU - McNulty, James P.

    AU - Niederehe, George

    AU - Ryan, Neal

    AU - Stuart, Gail

    AU - Thomas, Stephen B.

    AU - Tollefson, Gary D.

    AU - Vitiello, Benedetto

    PY - 2002/9/15

    Y1 - 2002/9/15

    N2 - As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.

    AB - As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.

    KW - Clinical trials

    KW - Mood disorders

    KW - Translation research

    UR - http://www.scopus.com/inward/record.url?scp=0037106942&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037106942&partnerID=8YFLogxK

    U2 - 10.1016/S0006-3223(02)01467-1

    DO - 10.1016/S0006-3223(02)01467-1

    M3 - Review article

    VL - 52

    SP - 631

    EP - 654

    JO - Biological Psychiatry

    JF - Biological Psychiatry

    SN - 0006-3223

    IS - 6

    ER -